Chronic kidney disease: the global challenge (Q36017142)

11 August 2017

1 reference

title

Chronic kidney disease: the global challenge (English)

1 reference

chronic renal insufficiency

11 August 2017

1 reference

A Meguid El Nahas

1

1 reference

PubMed ID

15664230

11 August 2017

Aminu K Bello

series ordinal

2

1 reference

PubMed ID

15664230

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

365

1 reference

11 August 2017

331-340

1 reference

11 August 2017

9456

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Should the K/DOQI definition of chronic kidney disease be changed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The okinawa screening program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Diabetes and renal failure in Indo-Asians in the UK--a paradigm for the study of disease susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

End-stage renal disease in African-American and white men. 16-year MRFIT findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Racial Differences in the Progression from Chronic Renal Insufficiency to End-Stage Renal Disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Proteinuria and the risk of developing end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Obesity and target organ damage: the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Smoking as a risk factor for end-stage renal failure in men with primary renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The association of caffeinated beverages with blood pressure in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Risk of end-stage renal disease associated with alcohol consumption.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Recreational drug use: a neglected risk factor for end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Analgesics and chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

End-stage renal disease and non-narcotic analgesics: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Growth factor pathways in proliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Plasticity of kidney cells: Role in kidney remodeling and scarring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Cell biology of the glomerular podocyte

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Renal fibrosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Proteinuria and its consequences in renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Mechanisms of tubulointerstitial fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Stem cells in renal biology: bone marrow transplantation for the treatment of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The transforming growth factor beta system in kidney disease and repair: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Smad3 as a mediator of the fibrotic response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Antagonism of nuclear factor kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Cell cycle regulatory proteins in glomerular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The diabetes prevention program and its global implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Lifestyle modification as a means to prevent and treat high blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Update on the management of hypertension: recent clinical trials and the JNC 7.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Effect of lipid reduction on the progression of renal disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

A strategy to reduce cardiovascular disease by more than 80%

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Targeting growth factors to the kidney: myth or reality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Signaling: focus on Rho in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Screening for chronic kidney disease: unresolved issues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Feasibility study of the early detection and treatment of renal disease by mass screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Screening for proteinuria in US adults: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Individual risk prediction and population-wide disease prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Progression, remission, regression of chronic renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Renoprotection: one or many therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Optimization of pre-ESRD care: the key to improved dialysis outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

Slowing the progression of chronic renal failure: economic benefits and patients' perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917789-7

7 January 2021

10.1016/S0140-6736(05)17789-7

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15664230